BofA warns Fed risks policy mistake with early rate cuts
Dorothy Trefon Capers, Senior Vice President and General Counsel of Xylem Inc. (NYSE:XYL), a $31.3 billion market cap water technology company with impressive 16.3% revenue growth over the last twelve months, recently executed significant transactions involving the company’s stock. On March 4, 2025, Capers sold 12,026 shares of Xylem common stock at an average price of $127.26 per share, amounting to a total sale of approximately $1.53 million. According to InvestingPro, the stock currently trades at $128.96, with analysts setting price targets ranging from $114 to $174.
In addition to the sale, Capers acquired a total of 12,026 shares through various transactions. On the same day, she exercised options to acquire 7,868 shares at a price of $86.76 per share and 4,158 shares at $101.09 per share. These acquisitions totaled approximately $1.10 million.
Furthermore, on March 5, Capers received an award of 1,398 restricted stock units, valued at $129.67 per unit, as part of Xylem’s incentive plan. This award is set to vest in one-third increments over the next three years.
These transactions reflect Capers’ active management of her holdings in Xylem, a leading global water technology company headquartered in Washington, D.C. The company maintains a GOOD financial health score according to InvestingPro, which offers 12 additional valuable insights about Xylem’s performance and prospects in its comprehensive Pro Research Report.
In other recent news, Xylem reported fourth-quarter earnings that exceeded analyst expectations, with adjusted earnings per share reaching $1.18, surpassing the consensus estimate of $1.13. The company also reported a 7% year-over-year revenue increase to $2.3 billion, exceeding the expected $2.18 billion. Despite these positive results, Xylem issued a cautious revenue forecast for 2025, projecting between $8.6 billion and $8.7 billion, which falls short of the $8.84 billion anticipated by analysts.
For the full year 2024, Xylem achieved revenue of $8.6 billion, marking a 16% increase on a reported basis and a 6% organic growth from 2023. Adjusted earnings per share for the year were $4.27, reflecting a 13% year-over-year increase. Citi analyst Andrew Kaplowitz recently raised Xylem’s stock price target to $152, up from $147, while maintaining a Buy rating. This adjustment follows a review of Xylem’s fourth-quarter results and its initial 2025 outlook.
Kaplowitz highlighted the company’s anticipated adjusted EBITDA margin expansion of 70 to 120 basis points as a positive indicator, despite a modest dip in organic growth expected for 2025. Xylem’s ongoing commitment to operational efficiency and financial performance is reflected in these developments, as the company continues to focus on growth and long-term shareholder value.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.